Pernix Therapeutics (PTX) Posts Q1 Loss of 62c/Share

Pernix Therapeutics (NASDAQ: PTX) reported Q1 EPS of ($0.62), which may not compare with the analyst estimate of ($0.02). Revenue for the quarter came in at $33.9 million versus the consensus estimate of $34.55 million.

On a non-GAAP basis, 1Q 2015 adjusted net loss was $4.0 million versus an adjusted net loss of $1.8 million last year.

On a pro- forma basis, Pernix had cash and cash equivalents of $57.5 million and $360.7 million of debt as of March 31, 2015. For the balance of the year, Pernix anticipates cash interest expense for its 12% Senior Secured Notes due 2020 and its 4.25% Senior Convertible Notes due 2021 will be approximately $16 million.

For earnings history and earnings-related data on Pernix Therapeutics (PTX) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Jefferies upgrades Five Below to Buy, sees path to TJX-like re-rating
• Azitra, Inc. (AZTR) Tops Q2 EPS by 54c